Review article: Gene therapy in gastroenterology and hepatology

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 823-836

  Forbes, S J ^a,b   Hodgson, H J F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; PLASMID DNA; PRODRUG; VIRUS VECTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CANCER; CYSTIC FIBROSIS; DRUG TARGETING; ELECTROPORATION; GASTROINTESTINAL DISEASE; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEMOPHILIA; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER DISEASE; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION;

EID: 0030840396     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00226.x     Document Type: Review

References (98)

1. Porter A. Gene targeting as an approach to gene therapy. In: Lemoine NR, Cooper DN, eds. Gene Therapy. London: Bios Scientific Publishers, 1996; 169-90.
2. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sei USA 1996; 93: 5185-90.
3. Kistner A, Gossen M. Zimmermann F. et al. Doxycycline-mediated quantitative and tissue-specific control of gene exprès-sion in transgenic mice. Proc Nat! Acad Sei USA 1997; 93: 10,933-8.
4. Fynan EF. \Vebster RG, Fuller DH, et al. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995; 17: 79-83.
5. Lagging M, Meyer K, Hoft D, et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995; 69: 5859-63.
6. Lau C, Soriano HE, Ledley FD, et al. Retroviral gene transfer into the intestinal epithelium. Hum Gene Ther 1995; 6: 1145-51.
7. Ponder KP. Analysis of liver development, regeneration, and carcinogenesis by genetic marker studies. FASEB J 1996; 10: 673-82.
8. Overturf K, Al-Dhalimy M. Tanguay R, et al Hepatocytes corrected by gene therapy are selected i;i vivo in a murine model of hereditary tyrosinaemia type 1. Nat Genet 1996; 12:. 266-73.
9. Sigal SH, Brill S, Fiorino AS, Reid LM. The liver as a stem cell and lineage system. Am J Physiol 1992; 263: G139-8.
10. Alison MR, Golding M, Sarraf CE, Edwards RJ, Lalani EN. Liver damage in the rat induces hepatocyte stem cells from biliary epithelial cells. Gastroenterology 1996: 110: 1182-90 (see Comments).
11. Moscioni AD, Rozga J, Neuzil DF, et al. In vivo regional delivery of retrovirally mediated foreign genes to rat liver cells: Need for partial hepatectomy for successful foreign gene expression. Surgery 1993; 113: 304-11.
12. Lieber A, Peelers MJ, Gown A, Perkins J, Kay MA. A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum Gene Ther 1995; 6: 1029-37.
13. Ferry N, Duplessis O, Houssin D, Danos 0, Heard JM. Retroviral-mediated gene transfer into hepatocytes in viYo. Proc Natl Acad Sei USA 1991; 88: 8377-81.
14. Breedis C, Young G. Blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-85.
15. Wu GY, Wilson JM, Shalaby F, et al. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J Biol Chem 1991; 266: 14,338-42.
16. Mahato RI, Kawabata K, Nomura T, Takakura Y, Hashida M. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sei 1995; 84: 1267-71.
17. Yang Y, Râper SE, Cohn JA, Engelhardt JF, Wilson JM. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sei USA 1993; 90: 4601-5.
18. Hickman MA, Malone RW, Lehmannbruinsma K, et al. Gene expression following direct injection of DNA into the liver. Hum Gene Ther 1994; 5: 1477-83.
19. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sei USA 1990; 87: 9568-72.
20. Kay MA, Baley P, Rothenberg S, et al. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sei USA 1992: 89: 89-93.
21. Schmid RM. Weidenbach H. Draenert GF, et al. Liposome mediated in vivo gene transfer into different tissues of the gastrointestinal tract. Z Gastroenterol 1994; 32: 665-70.
22. Seiden C, Calnan D, Morgan N, et al. Histidinemia in mice: a metabolic defect treated using a novel approach to hepatocellular transplantation. Hepatology 1995; 21: 1405-12.
23. Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sei USA 1994; 91:9519-23.
24. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res 1995; 12: 825-30.
25. Keating A, Toneguzzo F. Gene transfer by electroporation: a model for gene therapy. Prog Clin Biol Res 1990: 333: 491-8.
26. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal and gene gun innoculations. Proc Natl Acad Sei USA 1993; 90: 11478-82.
27. Qiu P, Ziegelhoffer P, Sun J, Yang NS. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther 1996; 3: 262-8.
28. Graham FL, Van Der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-67.
29. Bommineni VR, Chowdhury NR, Wu GY, et al. Depolymerization of hepatocellular microtubules after partial hepatectomy. J Biol Chem 1994; 269: 25,200-5.
30. Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sei USA 1993; 90: 2122-6.
31. Yanagihara I, Kaneda Y, Inui K, Okada S. Liposome-mediated gene transfer. In: Dickson G, ed. Molecular and Cell Biology of Human Gene Therapeutics. London: Chapman and Hall, 1995: 64-82.
32. Kato K. Nakanishi M, Kaneda Y, Uchida T, Okada Y. Expression of hepatitis B surface antigen in adult rat liver. J Biol Chem 1991; 266: 3361-4.
33. Tsichlis PN. Oncogenesis by Moloney murine leukemia virus. Anticancer Res 1987; 7: 171-80.
34. Hafenrichter DG, Wu X, Rettinger SD, et al Quantitative evaluation of liver-specific promoters from retroviral vectors after In vivo transduction of hepatocytes. Blood 1994; 84: 3394-404.
35. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lyses RNA tumour viruses. Nature 1975; 257: 612-4.
36. Kasahara N, Dozy AM, Kan YW. Injectable retroviral particles for human gene therapy. Adv Drug Delivery Rev 1995; 17: 213-26.
37. Straus SE. Adenovirus infections in humans. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press, 1984:451-96.
38. Ali M, Lemoine NR, Ring CJA. The use of DNA viruses as vectors for gene therapy. Gene Ther 1994; 1: 367-84.
39. Lee MG, Abina MA, Haddada H, Perricaudet M. The constitutive expression of the immunomodulatory gp!9 k protein in El-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995: 2: 256-62.
40. Kotin RM, Siniscalco M. Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc NatI Acad Sei USA 1997:87:2211-5.
41. de la Maza LM, Carter BJ. Molecular structure of adeno-associated virus variant DMA. J Biol Chem 1980; 255: 3194-203.
42. Takahashi T. Carbone D, Takahashi T, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992; 52: 2340-3.
43. Bookstein R, Demers W, Gregory R, et al p53 gene therapy In vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23: 66-77.
44. Schneider PM, Casson AG, Levin B, et al. Mutations of p53 in Barren's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996; 111: 32331.
45. Polkowski VV, van Lanschot JJ, Ten Kate FJ, et al. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 1995; 4: 163-71.
46. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver métastases after in situ transduction of a suicide gene. Proc Natl Acad Sei USA 1993; 90: 7024-8.
47. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994: 54: 6228-34.
48. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1997; 4: 725-32.
49. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1997; 6: 1055-63.
50. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994; 1: 170-5.
51. Cao G, Kuriyama S, Du P, et cil. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology 1997; 112: 501-10.
52. Kimura O, Yamaguchi Y, Gunning KB, et al. Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas. Hum Gene Ther 1994; 5: 845-52.
53. Goodarzi G, Gross SC, Tewari A, Watabe K. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol 1990; 71: 3021-5.
54. Offensperger WB, Offensperger S, Walter E, et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993; 12: 1257-62.
55. Moriya K, Matsukura M, Kurokawa K, Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem Biophys Res Commun 1996: 218: 217-23.
56. Wakita T, Vands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994; 269: 14,205-10.
57. Tokushige K, Wakita T, Pachuk C, et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996; 24: 14-20.
58. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sei USA 1993; 90: 11.548-52.
59. Askari F. DNA/protein complexes delivered in conjunction with adenovirus generate high-efficiency in vitro transfection: a powerful transfection reagent with potential broad applications. Hepatology 1993; 18: 1537-9.
60. Kurachi K, Yao SN. Gene therapy of hemophilia B. Thromb Haemost 1993; 70: 193-7.
61. Connelly S, Smith TAG, Dhir G, et al In vivo gene delivery and expression of physiological levels of human factor VIII in mice. Hum Gene Ther 1995; 6: 185-93.
62. Baru M, Axelrod JH, Nur I. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice. Gene 1995; 161: 143-50.
63. Smith TA, Mehaflcy MG, Kayda DB. et al Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993: 5: 397-402.
64. Kay MA, Landen CN, Rothenberg SR, et al In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sei USA 1994; 91: 2353-7.
65. Ledley FD. Hepatic gene therapy: present and future. Hepatology 1993: 18: 1263-73.
66. Kay MA, Rothenberg S, Landen CN, et al In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-9 (see Comments).
67. 7 Axelrod JH, Read MS, Brinkhous KM, Verma IM. Phenotypic correction of factor IX deficiency in skin fibroblasts of hémophilie dogs. Proc Natl Acad Sei USA 1990; 80: 51737.
68. Liu HW, Ofosu FA, Chang PL. Expression of human factor IX by microencapsulated recombinant fibroblasts. Hum Gene Ther 1993; 4: 291-301.
69. Brown MS, Goldstein JL, Havel RJ, Steinberg D. Gene therapy for cholesterol. Nat Genet 1994; 7: 349-50 (Letter; Comment).
70. Hoeg JM, Starzl TE, Brewer HB, Jr. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. Am J Cardiol 1987; 59: 705-7.
71. Li J, Fang B, Eisensmith RC, et al In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995; 95: 768-73.
72. Wilson JM, Grossman M, Wu CH, et al. Hepatocyte-directed gene transfer in viro leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J Biol Chem 1992; 267: 963-7.
73. Chowdhury JR, Grossman M, Gupta S, et al. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991: 254: 1802-5.
74. Weatherall D. Heroic gene surgery. Nat Genet 1994; 6: 325-6 (News; Comment).
75. Grossman M, Râper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to the liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-41 (see Comments).
76. Grossman M. Rader DJ, Muller DVV, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-54 (see Comments).
77. Morse JO, Lebowitz MD, Knudson RJ, et al. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. N Engl J Med 1977; 296: 1190-4.
78. Perlmutter DH. The celluar basis for liver injury in oantitrypsin deficiency. Hepatology 1991; 13: 172-85.
79. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease: genetic basis and startegies for therapy. J Clin Invest 1990; 85: 1343-52.
80. Ponder KP, Gupta S, Leland F, et al. Mouse hepatocytes migrate to liver parenchyma and function indefinately after intrasplenic transplantation. Proc Natl Acad Sei USA 1991; 88: 1217-21.
81. Kay MA, Li Q, Liu TJ, et al Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther 1992; 3: 641-7.
82. Jaffe HA, Danel C, Longenecker G, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1: 372-8.
83. Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child 1995; 72: 281-4.
84. Maeda H, Danel C, Crystal RG. Adenovirus-mediated transfer of human lipase complementary DNA to the gallbladder. Gastroenterology 1994; 106: 1638-44 (see Comments).
85. Cohn JA, Strong TV, Picciotto MR, et al Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105: 1857-64.
86. Grubman SA, Fang SL, Mulberg AE, et al Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 1995; 108: 584-92.
87. Niederau C, Stremmel W, Strohmeyer GVV. Clinical spectrum and management of haemochromatosis. Baillieres Clin Haematol 1994; 7: 881-901.
88. Feder JN, Gnirke A, Thomas W, et al A novel MHC class I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-108.
89. Cox T. Haemochromatosis: Strike while the iron is hot. Nat Genet 1996: 13: 386-8.
90. Hasegawa T, Tzakis AG, Todo S, et al. Orthotopic liver transplantation for ornithine transcarbamylase deficiency with hyperammonemic enccphalopathy. J Pediatr Surg 1995; 30: 863-5.
91. Stratford Perricaudet ID, Levrero M, Chasse JF, Perricaudet M, Briand P. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-56.
92. Shedlovsky A, McDonald JD, Symula D, Dove VVF. Mouse models of human phenylketonuria. Genetics 1993; 134: 1205-10.
93. Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. Acta Paediatr Suppl 1994; 407: 124-9.
94. Martin MG, Turk E. The molecular basis of inherited disorders of the gastrointestinal and hepatobiliary tracts. An update on recent progress. Gastroenterol Clin North Am 1995; 24: 4570.
95. Branchereau S, Ferry N, Myara A, et al. Correction of bilirubin glucuronyl transferase in Gunn rats by gene transfer in the liver using retroviral vectors. Chirurgie 1993; 119: 642-8.
96. Chowdhury NR, Hays RM, Bommineni VR, et al. Microtubular disruption prolongs the expression of human bilirubinuridinediphosphoglucuronate-glucuronosyltransferase-l gene transferred into Gunn rat livers. J Biol Chem 1996; 271: 23416.
97. Li Y, Togashi Y, Sato S, et al. Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary ' hepatitis. A model of Wilson's disease. J Clin Invest 1991; 87: 1858-61.
98. Bulfield G, Kacser H. Histidinaemia in mouse and man. Arch Dis Child. 1974; 49: 545-52.